Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Medipharm Labs Corp (TSX: LABS )

0.0700 UNCHANGED
Streaming Delayed Price Updated: 3:57 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 322,836
Open 0.0750
Bid (Size) 0.0700 (5,690)
Ask (Size) 0.0750 (2,200)
Prev. Close 0.0700
Today's Range 0.0700 - 0.0750
52wk Range 0.0600 - 0.1000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MediPharm Q2 Loss Narrows, Adjusted EBITDA Climbs As Gross Profit Improves Nearly 300% YoY
Cannabinoids-focused pharmaceutical company MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) announced on Wednesday financial results for the second quarter ended June 30, 2024, revealing an... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
This Cannabis Co With Significant Growth Potential And Other Hot Weed Stocks Soon To Report Earnings, What Investors Need To Know Now
Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF), a cannabis operator with vertical operations in Arizona and Ohio, said it will release its financial results for the second quarter ended June 30, 2024,... 
Via Benzinga
Topics Cannabis
Exposures Cannabis

Performance

YTD
+7.69%
+7.69%
1 Month
N/A
N/A
3 Month
+7.69%
+7.69%
6 Month
-12.50%
-12.50%
1 Year
-6.67%
-6.67%

More News

Read More
Executive Changes In Cannabis Industry You Should Know About, New Appointments & More
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabinoids-Focused MediPharm Boasts This Advanced Medical Cannabis Delivery Method
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabinoids-Focused Pharma Company, MediPharm, Sees Higher Q1 Revenue, CFO Touts 'Strong Financial Position'
Via Benzinga
This Cannabinoids-Focused Pharma Co. Sees 50% YoY Surge In Revenue In 2023, Trims Losses
Via Benzinga
Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil
Via Benzinga
Topics Cannabis
Exposures Cannabis Product Safety
Key Leadership Changes In Cannabis You Should Know About As We Head Into 2024
Via Benzinga
Topics Cannabis
Exposures Cannabis
MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report
Via Benzinga
MediPharm Settles Commercial Agreement Dispute With Tilray's Hexo For $9M
Via Benzinga
MediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's Next
Via Benzinga
MediPharm Labs Corp. to Acquire VIVO Cannabis Inc.
Via Newsfile
Topics Cannabis
Exposures Cannabis
MediPharm Labs Sees 16.5% QoQ Increase In International Medical Cannabis Sales, Announces New CEO
Via Benzinga
Topics Cannabis
Exposures Cannabis
MediPharm Labs Taps Bryan Howcroft as Chief Executive Officer And Director
Via Benzinga
MediPharm Labs To Provide Materials For Clinical Trial On CBD For Insomnia
Via Benzinga
MediPharm Labs Reports 24% QoQ Pop In International Sales, Q2 2021 Revenue Drops 63.6% YoY
Via Benzinga
MediPharm Labs Receives Canadian GMP Pharmaceutical Drug Establishment License
Via Benzinga
Another Near Billion-Dollar Cannabis Acquisition Signals More Hyper Valuations to Come
Via FinancialNewsMedia
Topics Cannabis
Exposures Cannabis
MediPharm Labs Extends Collaboration With German Medical Cannabis Distributor ADREXpharma
Via Benzinga
Topics Cannabis
Exposures Cannabis
MediPharm Posts Q1 2021 Results: What Cannabis Stock Investors Need To Know
Via Benzinga
Topics Cannabis
Exposures Cannabis
Number Of Cannabis Patents Granted In Europe & UK Growing At A Quick Pace
Via FinancialNewsMedia
Topics Cannabis Intellectual Property Law Enforcement
Exposures Cannabis Intellectual Property Legal
Adjupharm Signs Supply Agreement with MediPharm Labs, Paving Way for IM Cannabis-Branded Extracts Launch in German Market
From IM Cannabis Corp.
Via AccessWire
Topics Cannabis Law Enforcement
Exposures COVID-19 Cannabis Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.